HER2-positivity, absence of suspicious calcifications on mammography, treatment with dual HER2-blockade, near/complete response on MRI, absence of calcifications in DCIS on pre-NST biopsy and Ki67 expression > 20% in DCIS, were all factors predicting response to NST in univariate analysis [7]. Here, ERBB2 is linked to ductal breast carcinoma in situ.